Currently, prostate cancer is treated with a combination of radiotherapy, chemical castration, androgen receptor (AR) antagonists (hydroxyflutamide, bicalutamide), or inhibitors of steroidogenesis (abiraterone). Here, AR is linked to prostate cancer.